- Home
- IART vs CVAC Comparison
IART vs CVAC Comparison
Compare IART & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IART
- CVAC
- Stock Information
- Founded
- IART 1989
- CVAC 2000
- Country
- IART United States
- CVAC Germany
- Employees
- IART N/A
- CVAC N/A
- Industry
- IART Medical/Dental Instruments
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- IART Health Care
- CVAC Health Care
- Exchange
- IART Nasdaq
- CVAC Nasdaq
- Market Cap
- IART 1.2B
- CVAC 1.2B
- IPO Year
- IART 1995
- CVAC 2020
- Fundamental
- Price
- IART $15.38
- CVAC $5.35
- Analyst Decision
- IART Hold
- CVAC Hold
- Analyst Count
- IART 8
- CVAC 3
- Target Price
- IART $18.17
- CVAC $6.83
- AVG Volume (30 Days)
- IART 1.2M
- CVAC 473.7K
- Earning Date
- IART 11-03-2025
- CVAC 11-11-2025
- Dividend Yield
- IART N/A
- CVAC N/A
- EPS Growth
- IART N/A
- CVAC N/A
- EPS
- IART N/A
- CVAC 1.01
- Revenue
- IART $1,621,738,000.00
- CVAC $599,540,810.00
- Revenue This Year
- IART $5.74
- CVAC N/A
- Revenue Next Year
- IART $4.35
- CVAC $23.95
- P/E Ratio
- IART N/A
- CVAC $5.33
- Revenue Growth
- IART 3.53
- CVAC 675.15
- 52 Week Low
- IART $11.06
- CVAC $2.37
- 52 Week High
- IART $27.13
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- IART 58.46
- CVAC 44.68
- Support Level
- IART $14.52
- CVAC $5.34
- Resistance Level
- IART $15.69
- CVAC $5.41
- Average True Range (ATR)
- IART 0.64
- CVAC 0.04
- MACD
- IART -0.11
- CVAC -0.00
- Stochastic Oscillator
- IART 54.08
- CVAC 33.33
About IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.